

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **TATA Health International Holdings Limited**

### **TATA 健康國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1255)**

## **FURTHER DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS AND FURTHER DELAY IN DESPATCH OF THE 2024 ANNUAL REPORT AND POSTPONEMENT OF THE BOARD MEETING AND CONTINUED SUSPENSION OF TRADING**

Reference is made to the announcements made by the board (the “**Board**”) of directors (“**Director(s)**”) of TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 31 March 2025, 3 September 2025 and 15 September 2025 (the “**Announcements**”) in relation to, among others, further delay in publication of the Group’s annual results for the year ended 31 December 2024 (the “**2024 Annual Results**”) and the despatch of the Group’s annual report for the year ended 31 December 2024 (the “**2024 Annual Report**”). Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

### **FURTHER DELAY IN PUBLICATION OF THE 2024 ANNUAL RESULTS AND FURTHER DELAY IN DESPATCH OF THE 2024 ANNUAL REPORT**

The Board wishes to inform the shareholders of the Company that there will be a further delay in publication of the 2024 Annual Results and the despatch of the 2024 Annual Report as additional time is required by the Company and its auditor to finalise the contents of the 2024 Annual Results due to disruption of work schedule caused by super typhoon Ragasa. It is expected that the date of publication of the 2024 Annual Results will be postponed to a date on or before 26 September 2025.

## **POSTPONEMENT OF THE BOARD MEETING**

The Board hereby announces that the meeting of the Board for the purposes of, among other matters, considering and approving the 2024 Annual Results, and considering the recommendation of an annual dividend, if any will be postponed to 26 September 2025 (Friday).

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024 and will remain suspended pending the fulfilment of the resumption guidance. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**TATA Health International Holdings Limited**  
**Zhang Ming Qi**  
*Non-executive Director*

Hong Kong, 23 September 2025

*As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Chu Chun Ho, Dominic, Mr. Zhang Ming Qi and Mr. Chen Qi; and three independent non-executive Directors, namely, Ms. Huang Lin, Mr. Li Liang and Mr. Du Jianfeng.*